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ABSTRACT 
Cadherins are a superfamily of intercellular adhesion molecules essential for structural maintenance 
of tissue cohesion, precise primary tissue segregation and regulation of regeneration processes in 
adult. Cadherins are widely expressed in the vasculature. Adherens junctions and desmosomes, 
where cadherins are the intercellular adhesion transmembrane linkers, have been demonstrated in 
large and small arteries in vivo and their participation in correct organization of vascular smooth 
muscle architecture is doubtless. However, knowledge on precise functional roles for cadherin in 
healthy or diseased vascular smooth muscle is limited.  
T-cadherin is an atypical cadherin highly expressed on endothelial and smooth muscle layers of the 
vasculature. Dynamic T-cadherin expression on vascular smooth muscle in vivo has been reported in 
number of vascular pathologies including two major vasoproliferative disorders – atherosclerosis and 
restenosis. Functions and molecular mechanisms regulated by this molecule in the smooth muscle 
cell component of the vasculature are unknown. The primary functions of vascular smooth muscle 
cells (VSMC) are contraction and regulation of blood vessel tone. However, VSMC possess inherent 
plasticity: they can switch from mature contractile phenotype to a de-differentiated proliferative and 
synthetic phenotype in response to vascular injury, or local environmental cues signalling. Studies in 
this dissertation are aimed at establishing cellular functions for T-cadherin in VSMC contraction and 
phenotype plasticity and identifying mediating molecular mechanisms. 
First, we found that T-cadherin modulates non-metabolic insulin signalling via Akt/mTOR, which in 
turn leads to alterations in VSMC contractile competence and increased matrix remodelling. T-
cadherin overexpressing cells exhibited elevated constitutive levels of phosphorylated Aktser473, 
GSK3βser9, S6RPser235/236 and IRS-1ser636/639. Contractile machinery was constitutively altered in a 
manner indicative of reduced intrinsic contractile competence, namely decreased phosphorylation of 
MYPT1thr696 or MYPT1thr853 and MLC20thr18/ser19, reduced RhoA activity and increased iNOS expression. 
T-cadherin overexpressing VSMC-populated collagen lattices exhibited greater compaction which 
was due to increased collagen fibril packing/reorganization. These cells also exhibited a state of 
insulin insensitivity as evidenced by attenuation of the ability of insulin to stimulate Akt/mTOR axis 
signalling, phosphorylation of MLC20 and MYPT1, compaction of free-floating lattices and collagen 
fibril reorganization in unreleased lattices. 
Second, T-cadherin upregulation on VSMC, a phenomenon observed in VSMC-driven vascular 
pathologies (atherosclerosis and restenosis) promotes VSMC phenotype transition. T-cadherin 
upregulation in VSMC caused loss of spindle morphology, reduced/disorganized stress fibre 
formation, decay of SMC-differentiation marker proteins, increased levels of β-catenin and cyclin D1, 
and migro-proliferative behaviour. Genetic T-cadherin ablation, on the other hand, enforced 
differentiated phenotype. T-cadherin hyperactivates Akt axis signalling and inactivates classical 
downstream effector GSK3β. Ectopic adenoviral-mediated co-expression of constitutively active 
GSK3β restored morphological, molecular, and functional characteristics of differentiated VSMC in T-
cadherin overexpressing cells, suggesting that GSK3β inactivation is essential for T-cadherin induced 
VSMC de-differentiation. 
The studies have revealed novel cadherin-based modalities to regulate VSMC sensitivity to insulin 
and phenotype plasticity, which is achieved via Akt/mTOR axis hyperactivation and altered 
downstream effector signalling. 
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INTRODUCTION 
1. Smooth muscle and its function 
1.1. Smooth muscle  
Smooth muscle is distributed in many parts of the body and has varied but highly specialized 
functions based on coordinated cycles of contraction and relaxation. Smooth muscle is mostly found 
in the hollow and tubular organs where it ensures directional movement of body fluids, or regulates 
organ size and shape. Organized in sheets or arrays of bundles, smooth muscle consists of uninuclear 
elongated, spindle shaped cells embedded and enwrapped in large amounts of extracellular matrix 
(ECM). In large elastic arteries ECM can constitute more than 50% of the media volume. Most of this 
ECM is produced and maintained by smooth muscle cells (SMC) [1].  
1.2. Smooth muscle cells  
The characteristic elongated spindle shape of SMC in mature smooth muscle is dictated by its 
principal function, which is to contract and generate mechanical output needed for the function of a 
particular organ. However, within the adult organism SMC expressing common set of classical marker 
genes may be very heterogeneous in morphology. This depends on cell location (e.g. veins vs. 
arteries), its embryological origin, or the organ context [2]. Smooth muscle is non-striated. 
Contractile apparatus of the SMC, primarily actin and myosin filaments, is attached to the cell 
membrane and criss-cross the entire cell body. The cell membrane is rich in ion channels, cell-to-cell 
and cell-to-matrix junctions, all dedicated to ensure effective communication with the environment 
and robust action coordination with neighbouring cells [1]. Smooth muscle function is based on 
cooperation between mature myocytes, as well as between myocytes and surrounding extracellular 
matrix. Smooth muscle function is controlled by a broad variety of stimuli – neural, mechano, 
hormonal, light, changes in temperature, or self SMC-induced myogenic signal propagation [1].  
Vascular smooth muscle cells (VSMC) are stromal cells of the blood vessels. VSMC maintain normal 
blood pressure and provide structural stability and resistance to the mechanical stress in the vessels 
[1]. In early development VSMC in arteries and veins and pericytes in capillaries muscularize primary 
vessels formed by endothelial cells (EC), providing structural stability and functionality [3]. Well-
coordinated cycles of smooth muscle contraction and relaxation adjust vessel diameter and regulate 
hemodynamics. In addition, VSMC synthesize ECM, which helps to resist the high pressure load of 
circulating blood and prevent physical permeability in large vessels [4].  
1.3. Smooth muscle contraction 
Multiple pathways exist for activation of SMC contraction. Cytosolic Ca2+ plays a central role in 
initiating and regulating contraction. The key effector in SMC contraction/relaxation signalling and 
mechanics is the 20 kDa myosin light chain protein (MLC20) [1]. In its active state MLC20 activates Mg2+ 
ATPase function of myosin and enables it to bind and slide along the actin filament, eventually 
resulting in cell and muscle contraction [5]. 
Ca2+-dependent MLC20 activation is mediated by myosin light chain kinase (MLCK), which in turn 
depends on the Ca2+-calmodulin system. The system is activated by an increase in free cytoplasmic 
Ca2+; this happens when extracellular stimuli open Ca2+ channels and extracellular or sarcoplasmic 
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free Ca2+ influx in to intracellular space. Intercellular Ca2+ complexes with calmodulin, activates MLCK 
and thereby initiates SMC contraction. Ca2+-dependent SMC contraction is controlled by signals 
which regulate activity of numerous receptor operated Ca2+ channels (ROCC), located on the cell 
membrane or on sarcoplasmic reticulum [5]. Well known ligands such as prostaglandins, endothelin-
1, norepinephrine, angiotensin II and vasopressin activate ROCC and allow Ca2+ influx [6]. Additional 
control is provided by voltage-dependent channels.  
A second contraction signalling mechanism in SMC is independent of Ca2+and is called Ca2+ 
sensitisation. Ca2+-sensitisation is mediated by small Rho GTPase RhoA and Rho associated kinase 
(Rho-kinase) [7]. In addition to Ca2+ channel control, vasoconstrictors can activate the RhoA/Rho-
kinase signalling pathway. This pathway regulates myosin light chain phosphatase (MLCP) and MLC20 
activities (active MLCP directly binds to and dephosphorylates/inactivates MLC20) RhoA recruits and 
activates Rho-kinase, which negatively regulates MLCP activity by phosphorylation and heightens 
SMC contraction [8]. In addition, Rho-kinase directly phosphorylates and activates MLC20, further 
promoting SMC contractility [9].  
SMC relaxation is achieved by removal of contractile stimuli and reduction of intracellular Ca2+ or by 
inhibition of RhoA/Rho-kinase signalling [5]. Vasodilators act by closing Ca2+ channels, activating 
outward Ca2+ pumps, and inhibiting RhoA/Rho-kinase pathway signalling. Reduction of free cytosolic 
Ca2+ activates MLCP, which dephosphorylates/ inactivates MLC20, enabling the cell to switch into 
relaxation phase. SMC relaxation can be induced by natriuretic peptides and vasodilators adenosine, 
adrenomedulin, nitric oxide (NO), or insulin.  
Insulin is a versatile signalling molecule and regulates multiple processes in VSMC. In addition to its 
“canonical” metabolic function, insulin plays an important role in maintenance of differentiated 
VSMC phenotype (see section 4.2.1.3.), and reducing vascular tone [10]. As a vasodilator insulin 
affects both Ca2+-dependent, and Ca2+-independent SMC contraction. Insulin regulates Ca2+-
dependent contractile signalling via inhibition of Ca2+ influx and induction of Ca2+ efflux [11-13]. 
Insulin affects Ca2+-independent contractile signalling by targeting RhoA activity. Insulin signalling 
induces NO synthesis by activation of inducible nitric oxide synthase (iNOS) and endothelial nitric 
oxide synthase (eNOS), both of which are found in SMCs [14]. NO activates guanylate cyclase, and 
induces production of cGMP. cGMP activates cGMP-dependent protein kinase α (PKG I α), which 
binds and inactivates RhoA (by phosphorylation on Ser188) [15]. In addition, insulin reduces RhoA 
translocation to the membrane by inhibition of geranyl-geranyl transferase [16]. Insulin inhibitory 
pathway on SMC contraction is phosphatidylinositol-3-kinase (PI3K) and Akt signalling dependent 
[17,18]. 
1.4. Vascular smooth muscle repair and renewal (turnover) 
VSMC have functional plasticity. In addition to regulation of hemodynamics and provision of 
structural support, VSMC fulfil vascular repair functions. Pre-existing mature VSMC are the major 
contributors of smooth muscle repair and vessel renewal [19]. Mature VSMC retain high degree of 
cellular plasticity and can switch their phenotype from quiescent-contractile to migro-proliferative 
and synthetic. On demand or guided by environmental cues fully differentiated VSMC can adjust 
their phenotype by de-differentiation in order to adopt reparative functions. VSMC undergoing de-
differentiation lose contractile machinery and competence, increase ECM production and intensify 
matrix remodelling, become migratory, and re-enter cell cycle. Once vessel homeostasis and 
structural integrity is restored, de-differentiated phenotype then re-differentiates back to the 
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mature, contractile state [20]. In a healthy vascular wall individual VSMC de-differentiation occurs at 
a low event rate and ensures constant vascular wall renewal, or in case of injury, repair to damaged 
tissue. However, when phenotype transition controlling mechanisms fail, VSMC plasticity is 
detrimental. Persistent pathological VSMC-driven reparation significantly contributes to life 
threatening conditions like atherosclerosis, restenosis, or graft failure [19]. Despite high demand for 
improved cardiovascular therapeutics and intense research, mechanistic pathways controlling VSMC 
phenotype remain incompletely understood.  
2. Cardiovascular diseases 
Cardiovascular diseases (CVD) are the major cause of death worldwide [21] (Fig.1.). CVDs are heart or 
vasculature dysfunctions which include coronary heart diseases causing heart attacks, 
cerebrovascular disease causing stroke, hypertension, peripheral artery disease, rheumatic heart 
disease, congenital heart disease and heart failure.  
 
The latest (2014) global status report of noncommunicable diseases published by WHO estimated 
17.5 million CVD caused deaths in 2012, which represents 31% of all deaths worldwide and more 
than half of all deaths across the European Region. 7.4 million of all global CVD deaths were due to 
coronary heart disease, and 6.7 million due to the stroke together taking 80% of all CVDs [21]. 
Considering some global demographic and socioeconomic trends – population aging, economic 
growth in Asia, and endemic spread of obesity in developed countries – high cardiovascular death 
rates will remain an unsolved problem. It is predicted that the proportion of CVD death will only rise 
[22]. The introduction of statin therapy and drug-eluting stents a few decades ago offered major 
breakthroughs in the clinical management of CVD, however, novel, more targeted and, importantly, 
low cost therapeutic and early diagnostic methods are needed. About 75% of CVD deaths occur in 
low- and middle- income countries [21], bringing additional economic burden to the weak 
economies.  
The highest risk factors for CVDs are behavioural: tobacco, alcohol use and bad body biochemistry 
(unbalanced diet, low physical activity and obesity). Higher CVD mortality rates in women suggest 
that important, but not yet well understood non-environmental factors play a role in cardiovascular 
health. Ultimately, deeper understanding of basic cardiovascular physiology and CVD mechanisms is 
needed. Better awareness of the major risk factors and lifestyle adjustments would certainly help to 
reduce the premature deaths from CVDs, however a range of diverse strategies is needed to reach 
 
Fig.1. Global deaths rates by the cause of deaths under age of 70 years. Cardiovascular diseases are 
leading causes of deaths worldwide - 31% of all deaths. Ischemic heart diseases and cerebrovascular 
diseases have the highest mortality rates among the cardiovascular diseases. 2012 estimates by WHO [21]. 
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substantial result [23], and fundamental research should be one of them. – Past results show that 
cardiovascular research is a highly cost effective research – the returns from past cardiovascular 
research have been substantial, yielding 9% of internal rate of return in the UK [24], and 20.6% in 
Canada [25]. 
2.1. Vascular smooth muscle dysfunction driven cardiovascular diseases 
Smooth muscle and SMC have been studied or used as model systems for decades, yet we still do not 
understand their biology well enough to be able to prevent or treat the smooth muscle-related 
pathophysiological conditions effectively. Smooth muscle disorders are numerous, and mostly non-
treatable. Highest mortality rate bearing CVDs are caused by pathological vessel narrowing, which on 
cellular and molecular levels is largely the outcome of not yet therapeutically controllable processes 
and inadequate VSMC response to changes in body biochemistry. 
2.1.1. Atherosclerosis and restenosis 
Coronary artery diseases (CAD) leading to ischemic heart disease and stroke are the most common 
among cardiovascular diseases and the major causes of death worldwide (Fig.1.). CAD arises from 
progressing atherosclerosis, a multiplex disease caused by disbalanced lipid metabolism and 
maladaptive immune reaction followed by inadequate vascular cell response [26-28]. Atherosclerosis 
is characterised by chronic vascular wall inflammation, progressive narrowing of the vessel lumen 
and eventual plaque formation. 
An initial step in atherosclerosis is driven by EC. Activated EC mediate immune cell adhesion to the 
vascular wall and monocyte infiltration to the intima where they initiate inflammation. Appearance 
of neointima is observed before formation of atheroma. Growth factor- and inflammatory cytokine-
activated intimal VSMC proliferate rapidly and produce large amounts of ECM. In addition, intimal 
growth is further exacerbated by infiltration of medial VSMC which migrate to the intima in response 
to platelet-derived growth factor (PDGF) and other cytokine stimuli. This eventually culminates in 
vascular wall thickening and narrowing of the lumen [19].  
Monocytes which infiltrate to the expanding intima mature to macrophages, uptake high amounts of 
lipids and transform into foam cells [27]. In response to inflammatory factor stimulation and 
cholesterol loading, VSMC also acquire macrophage-like phenotype; they start to express 
macrophage and mesenchymal stem cell (MSC) markers, uptake lipids by endocytosis/phagocytosis 
eventually turning into foam cells [29-31]. Foam cells undergo apoptosis or necrosis and form 
cholesterol deposits, which accumulate and form a necrotic core. Further infiltration of VSMC and 
immune cells and chronic inflammation leads to necrotic core growth [32]. Ultimately, progression of 
such plaques can lead to rupture of the vessel wall and vessel thrombosis which hinders blood supply 
to the heart muscle or brain, causing myocardial infraction or stroke, respectively. Atherosclerotic 
plaques, covered by thick VSMC and VSMC-derived ECM cap are considered stable and rarely rupture 
[33]. However, if the inflammatory process progresses further, fibrous cap-forming VSMC undergo 
apoptosis which leads then to thinning of the fibrous cap and plaque rupture [34].  
Altered lipid metabolism and low density lipoprotein (LDL) pathway plays central role in 
atherosclerosis initiation and progression [32]. Statins, the inhibitors of hydroxymethyl glutaryl 
coenzyme A reductase, are the most efficient drug currently used as a mainstream therapy in 
atherosclerosis patients. However, statins do not cure the disease completely, and in about 20% of 
all patients statins are ineffective in prevention of vascular events [34,35]. Surgical interventions (e.g. 
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angioplasty) have similar failure rates (16-20%) [36,37] since endovascular procedures frequently 
lead to restenosis, which is a re-narrowing of the vessel caused primarily by excessive smooth muscle 
proliferation (hyperplasia) and ECM deposition [38].  
Until very recently, it was widely accepted that atherosclerosis is an immune cell-driven disease, and 
VSMC play only a marginal role [32]. This was mostly due to unreliable lineage tracing methods and 
an overlooked fact of extensive phenotype plasticity in both cell lineages (hematopoietic and SMC) 
within the microenvironment of atherosclerotic plaque [28]. VSMC within the lesion lose most of the 
SMC markers and can express macrophage and mesenchymal stem cell (MSC) markers, while 
macrophages may begin to express Acta2 and other SMC markers. Use of traditional immunolabeling 
in advanced atheromas may thus lead to misidentification of cell type. The need for revision of cell 
identification methods was urged by an accumulating number of studies showing that identification 
of cell origin in the atheroma by conventional methods might be very inaccurate. One study reported 
that 50% of foam cells in the advanced atheroma expressed smooth muscle (SM)-α-actin (classical 
SMC marker), as well as macrophage marker CD68 [31]. A study which used material derived from 
cross-gender bone marrow transplantation subjects found that >10% of SM-α-actin positive cells 
within atheroma is of hematopoietic origin [39]. A very recent study which used mouse genetic 
manipulations to track cell lineage showed that about 30% of all cellular mass within atherosclerotic 
lesions are phenotypically modulated SMCs, variously expressing SMC, macrophage or MSC markers, 
and that more than 80% of all of these cells would have been misidentified with conventional 
labelling methods [28].  
The study by Shankman, Gomez et al. demonstrated the existence of transcription factor-specific 
guidance of SMC phenotype in vivo, suggesting that VSMC phenotype transition in atheroma can be 
manipulated in order to increase plaque stability. Krüppel-like factor 4 (KLF4) is one of the most 
powerful SMC phenotype transition regulating factors (see section 4.1.2.), which guides SMC to 
acquire a pro-inflammatory macrophage-like phenotype. KLF4 knockout results in both formation of 
smaller and more stable atheromas due to the enrichment of SMC-like cells which form the fibrous 
cap, and loss of the pro-inflammatory, macrophage-like SMC population [28]. 
These findings confirm the importance of VSMC phenotype transition in atherosclerosis. Previously 
assumed protective role of VSMC in atheroma stabilization is only one of many functions that VSMC 
can assume via phenotypic switching. As a large body of in vitro data suggests, VSMC plasticity is 
remarkable and can lead to acquisition of many functionally distinct phenotypes (synthetic SMC, 
macrophage-, MSC- chondrogenic- or osteogenic-like cells), with very different outcomes in disease 
progression. Moreover, VSMC phenotype transition is an environmental cue-guided, rather than 
spontaneous process and can be manipulated in order to reduce the degree of disease pathogenesis. 
To explore this option, a deeper understanding of basic molecular pathways controlling VSMC 
phenotype transitions, the identification of environmental cues which regulate it, and the 
development of therapeutic tools to manipulate VSMC phenotype transition are of crucial 
importance.  
2.1.2. Cerebral microangiopathy 
Cerebral microangiopathy or small vessel disease (SVD) is another cause of vascular dementia and 
strokes [40]. Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) is caused by defective Notch signalling in VSMC, which occurs due to 
the dominant Notch3 mutation [41]. It was long thought that CADASIL occurs due to the loss of 
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Notch signalling, but accumulating evidence now supports that mutant Notch3 switches canonical 
Notch signalling to some other mode and modulates VSMC phenotype [42]. Progressing CADASIL 
leads to VSMC loss in small arteries, vessel stenosis, resting cerebral blood flow reduction, 
accumulation of ECM components (collagens and laminin) and osmiophilic material, and early death. 
No specific therapies are available to stop the progression of CADASIL or treat it [42].  
2.1.3. Marfan syndrome 
Marfan syndrome is an intrinsic monogenic disorder which targets VSMC and shifts vascular VSMC 
phenotype towards a more differentiated state. VSMC “over-differentiation”-caused vascular 
instability in Marfan syndrome illustrates well the importance of balanced VSMC phenotype plasticity 
for normal vascular function. 
Marfan syndrome is caused by mutations in fibrilin-1, an ECM protein encoding gene. Fibrilin-1 is a 
structural component of connective tissue, but also a negative regulator of transforming growth 
factor-β (TGF-β) activity (fibrilin-1 bound TGF-β is inactive). TGF-β is a pro-differentiation cytokine in 
VSMC (see section 4.2.1.2.). Reduction in fibrilin-1 abundance results in excessive TGF-β signalling, 
which locks VSMC in a differentiated state and suppresses their reparatory and synthetic function. 
VSMC “over-differentiation” adds to structural and functional fragility of the vessels with increased 
risk of aortic aneurism formation and aortic dissections, which are the major causes of early death in 
Marfan syndrome [43,44]. 
2.1.4. Hypertension 
Systemic hypertension is another circulation dysfunction, where VSMC are the targets of “upstream” 
pathophysiological changes. Endocrine or kidney dysfunction, aging, metabolic syndrome, or other 
not yet well understood processes increase vasoconstrictor signalling which manifests as a vascular 
smooth muscle mediated disorder [45].  
Hypertension is a systemic and chronic disease characterized by high arterial pressure and increased 
vascular resistance. Mechanistically, hypertension is the outcome of alterations in renin-angiotensin-
aldosterone or/and calcium-calmodulin systems [46]. Abnormalities in vasoconstrictor signalling 
enhance protein kinase C (PKC) and Rho-kinase signalling, which lead to VSMC hypertrophy (elevated 
contractile protein synthesis), increased VSMC contractility, vascular remodelling and extensive ECM 
synthesis resulting in increased vascular wall rigidity [47,48]. Constant exposure to enhanced and 
sustained mechanical stretch activates mitogen-activated protein kinase (MAPK) pathway and 
promotes VSMC proliferation [49]. In addition to dysregulation in upstream signalling, VSMC 
hypersensitivity to calcium or vasoconstrictor signalling is also often observed in hypertension [50], 
suggesting that in some cases intrinsic VSMC defects can be responsible for disease development as 
well.  
Medial hypertrophy and arterial resistance cause permanent changes in arterial architecture and 
worsen high blood pressure. Untreated hypertension can progress to hypertensive heart disease, 
stroke, aortic aneurisms or kidney failure. It highly promotes the development and progression of 
other conditions such as diabetes, endothelial dysfunction or atherosclerosis [45]. 
2.1.5. Pulmonary arterial hypertension 
Similarly to systemic hypertension, medial VSMC layer enlargement, intimal thickening and increased 
pulmonary artery resistance are observed in pulmonary arterial hypertension (PAH). These 
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anatomical changes restrict blood circulation between the lungs and the heart, which ultimately can 
result in right-sided heart failure. The causes of PAH can be very varied and multiplex with not yet 
identified molecular mechanisms or no direct relations to VSMC dysfunction. Familial PAH however is 
caused by intrinsic genetic VSMC defects, namely the loss-of-function mutation in bone 
morphogenetic protein (BMP) receptor-2. Reduced pro-differentiation BMP signalling in pulmonary 
artery VSMC and EC of familial PAH patients translates into weaker SMAD1-mediated p38/MAPK 
signalling repression, VSMC de-differentiation and hyperproliferation [51,52]. Extensive VSMC 
proliferation and matrix secretion causes enlargement of the intima and narrowing of the pulmonary 
artery.  
2.1.6. Role in non-cardiovascular diseases. Cancer metastasis 
Cancer does not belong to the group of CVDs. However, VSMC function might play an important role 
in the progression of this disease. Highly metastatic tumours often have poorly developed leaky 
blood vessels. This is caused by pericyte failure to differentiate and muscularize newly formed vessel 
[53]. It is not known whether leaky cancer vessels are the result of cancer microenvironment 
signalling, or the pre-existing and cancer spreading-permissive tissue dysfunction. It has been shown 
that the molecular signature comprising 17 genes in highly invasive tumours contained 4 pericyte 
differentiation marker genes (all downregulated) [54]. Leaky vessels favour physical cancer cell 
spreading and facilitate haemorrhage and inflammatory processes within the tumour, which further 
promotes tumour growth [55]. The role of VSMC phenotype switching in cancer pathogenesis is 
understudied, and the possible mechanistic basis of impaired tumour blood vessel maturation from 
the perspective of VSMC biology is not yet understood [56]. 
3. Vascular smooth muscle cell plasticity 
3.1. Phenotype modulation, phenotype switching and phenotype transition 
The term “phenotypic modulation” was introduced 
by Julie Chamley-Campbell et al. more than 30 
years ago [57] to describe the sum of 
morphological changes that VSMC undergo when 
cultivated in vitro. Now, together with synonymous 
“phenotype switching” or “phenotype transition” it 
envelops all functional-, structural- and molecular-
level alterations that smooth muscle cells undergo 
in response to changing environmental cues, and it 
is no longer limited to in vitro cultures [19]. 
VSMC-specific marker expression is a classical and 
one of the most important phenotype 
characteristics used to describe VSMC phenotype. 
Decreased expression of VSMC differentiation 
markers (mostly vital components of VSMC 
contraction machinery and cell anchorage (e.g. 
smooth muscle SM-α-actin, SM myosin heavy 
chain, calponin, h-caldesmon)) is universally 
accepted as an indicator of VSMC de-
differentiation. As levels of VSMC-specific marker 
          
Fig.2. VSMC phenotype plasticity. In vascular 
injury, or guided by environmental cues, fully 
differentiated SMC de-differentiate by losing 
contractile apparatus (blue gradient illustrating 
expression intensity on the left) and re-enter cell 
cycle. Once tissue repair is complete or de-
differentiation stimuli removed, SMC re-
differentiate fully regaining contractile function. 
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expression decline, expression of other proteins often involved in cell cycle progression or ECM 
components (e.g. collagen I, matrix-metalloproteinases (MMPs), calmodulin, cyclins) increases 
(Fig.2.). 
SMC marker decay and morphology changes together with altered functional characteristics, 
increased migration and hyper-proliferation, are the indications of a full VSMC phenotype switch. It is 
important to note that the mentioned characteristics describe the “averaged”, or “ideal” de-
differentiation status. In the injured or diseased vessel, populations of de-differentiated SMC can be 
very diverse in the grade of de-differentiation, but also because of phenotype divergence due to 
either exposure to different environmental cues and/or due to their different embryologic origins 
(even in a healthy adult vessel smooth muscle is very heterogeneous and resembles mosaic 
architecture [19]). Upon exposure to different environmental cues VSMC can acquire a spectrum of 
phenotypes: contractile-quiescent, migro-proliferative synthetic, osteogenic-, macrophage-, or MSC-
like [28].  
Although VSMC phenotype switching is a major mechanism for vessel renewal and repair, alternative 
mechanisms within the vessel might also exist. - Multipotent vascular stem cells which can 
differentiate to VSMC have been found in vascular wall [58]. However, the importance and 
contribution of these cells for vessel renewal and repair is not yet clear [59].  
3.2. Experimental models to study VSMC plasticity 
Experimental restenosis of the rat carotid artery after balloon injury is the most commonly used in 
vivo model to study VSMC plasticity. Rat carotid balloon injury is made by repeatedly inflating and 
withdrawing balloon catheter in the carotid artery in order to mechanically remove the endothelial 
lining [60]. Such injury induces vessel remodelling responses – intimal SMC proliferation, matrix 
production and medial SMC invasion to the intimal space (all via phenotype transition), – which 
result in neointima formation and growth. This model offers robust reproducibility and has been 
used to study cellular, biochemical and molecular aspects of vessel repair, and also serves as a “proof 
of concept” tool for verification of in vitro findings [61].  
The ApoE-deficient mouse (ApoE-/-) is the most popular in vivo model to study atherosclerosis. ApoE 
is a major apoprotein of the chylomicron and is essential for the normal catabolism of triglyceride-
rich lipoprotein constituents. Due to the impaired clearing of plasma lipoproteins ApoE-/- mice 
spontaneously develop hypercholesterolemia and atherosclerosis in a very short time – 3 months if 
fed a normal chow. The process can be accelerated by Western-type diet chow containing high levels 
of fat and cholesterol. The close resemblance of atherosclerotic lesions developed by this mice to 
those in human atheroma together with short disease development time makes this model the most 
attractive in vivo model to study atherosclerosis [62].  
Human- or animal-derived primary SMC tissue cultures have been used for decades to study SMC 
phenotype plasticity and contraction mechanisms. Contractile VSMC collected from human or animal 
vessel and cultured in vitro start to de-differentiate immediately due to the exposure to the high 
concentration of growth factors present in medium [63]. Growth factor withdrawal from the culture 
(serum starvation) reverts the phenotype to the differentiated state [64]. This phenomenon is very 
useful to study factors and conditions regulating SMC phenotype plasticity. However, primary SMC 
cultures have a number of inherent limitations which can lead to irreproducibility or generation of 
artefacts. Vascular smooth muscle is a highly heterogenic tissue, composed of different SMC 
subtypes derived from at least eight independent origins, each of which can respond differently to 
the applied stimuli and acquire diverse phenotypes [65]. High heterogeneity exists not only between 
different segments of the vessel, but also within the same vessel segment: therefore small 
inaccuracies in tissue isolation can lead to high variability in resulting primary cultures. This can be 
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Fig.3. Living three-dimensional 
microvascular network – a blood vessel 
on a chip. The in vitro 3D perfusable 
model system used to study angiogenesis 
and thrombosis [68]. Additional system 
components (e.g. lymphocytes, signalling 
molecules, antibodies, inhibitors) can be 
introduced temporarily or constantly with 
the culture medium that constantly flows 
through the channels. Adapted from [69]. 
further complicated by the variations in VSMC isolation and cultivation methods which can lead to 
conflicting result between different laboratories [56]. Isolation of SMC by tissue explant method 
preselects primarily for cells which have higher migration capacity. Isolation by enzymatic digestion is 
prone to fibroblast contamination and also high variability between isolates prepared on different 
occasions due to tissue “under-digestion” or “over-digestion” [66]. Thus, the method of isolation will 
markedly affect the dominance of different sub-populations in resulting cell cultures. Moreover, 
human VSMC isolates are susceptible to quick senescence and are often “preconditioned” by donors’ 
age, gender or received treatments.  
SMC phenotypic transition in the mature vessel involves 
the reactivation of embryonic stem cell pluripotency 
genes, which closely resemble SMC behaviour during 
vessel development [29]. Similarly like during de-
differentiation, in early vasculogenesis SMC are highly 
migro-proliferative and exhibit intensive ECM production 
and remodelling [56]. Due to phenotypic similarities 
between SMC phenotypes observed in de-differentiation 
and vasculogenesis, stem cell-derived tissue culture lines 
primarily designed to study developmental 
differentiation are often used to investigate SMC 
phenotype transition. Unlike primary SMC cultures, stem 
cell-derived cell lines offer high origin purity and can be 
used to study SMC origin-specific phenotype plasticity 
aspects.  
Several neural crest stem cell-derived and immortalized 
cell lines (e.g. Monc-I, JoMaI) are used as in vitro SMC 
differentiation models. TGF-β1 stimulation induces quick 
and robust differentiation toward SMC lineage in these 
cell lines. However, as models to study full SMC 
differentiation these lines are limited by the constant or 
temporal oncogene expression that is used as the 
immortalization instrument in parental stem cells. C-myc, 
or v-myc can interfere with response to the stimuli, or 
with the SMC phenotype transition program [67].  
Most popular mesoderm stem cell-derived models include 10T1/2 cells and human embryonic stem 
cell-derived mesenchymal cells (hES-MCs). Similarly to neural crest stem cell-derived lines, 
mesoderm-derived models differentiate to SMC upon stimulation with TGF-β1. SMC derivatives from 
10T1/2 and hES-MCs can reach higher differentiation status than Monc-I and JoMaI cells. TGF-β1-
stimulated 10T1/2 and hES-MCs can acquire a functional SMC phenotype as evidenced by expression 
of SM myosin heavy chain (the most stringent de-differentiated SMC marker), and responsiveness to 
contractile stimuli [68].  
Standard in vitro culturing eliminates many important environmental cues (e.g. three-dimensionality 
and (blood) flow stimulation), but is still the most commonly used method to manipulate molecular 
networks and study cellular aspects of SMC plasticity in the controlled environment. On the other 
hand, in vivo methods suffer from variability, limited possibilities for real-time condition control or 
read-out, and differences between animal and human physiology. Fast advancements in 
microfluidics, tissue printing and organ-on-a-chip technology are opening new ways to integrate the 
best parts of in vitro and in vivo models and develop easily modifiable, living tissue-like systems that 
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allow dynamic control and real-time analysis. Living three-dimensional microvascular networks 
composed of endothelial cells and mural cells (pericytes) have been used successfully to study 
angiogenesis and thrombosis [69,70] (Fig. 3.). Atherosclerosis on a chip is anticipated in the near 
future.  
4. Plasticity pathways 
As in every biological process, so in VSMC phenotype transition, environmental guidance is 
transmitted and regulated on many levels: signal generation, signal transduction, gene transcription 
and epigenetic (chromatin modification). Crucial regulators of VSMC phenotype transitions are 
emerging in all regulatory levels.  
4.1. Transcriptional regulators 
4.1.1. SRF and Myocardin – two major VSMC transcriptional regulators 
At the transcriptional level the key element for VSMC phenotype modulation is serum response 
factor (SRF). SRF is an evolutionary conserved and ubiquitously expressed transcription factor, which 
binds to a 10 base pair CArG-box sequence (CC[A/T]6CC) that is predominantly found in muscle and 
cytoskeletal genes [71]. SRF functions by responding to two often opposing signals – growth vs. 
cytoskeleton architecture – which in the context of VSMC plasticity translates into proliferation and 
de-differentiation vs. quiescence and contractile competence. In a simplified view, SRF integrates 
signals reaching it via two pathways, namely the MAPK cascade, or pro-differentiation stimuli 
transmitted via small Rho GTPases and actin. (Parts of Rho GTPases and actin branch signalling can 
be used by growth factor signalling to induce VSMC de-differenciation as well, but in different 
molecular contexts). SRF was first discovered as a growth inducer [72]. It later become clear that in 
this function SRF can be replaced by other factors [73], [74], but for organization of functional 
cytoskeleton and effective contractile machinery, SRF is absolutely indispensable. Srf knockout 
mouse embryos die in early development due to the inability of mesodermally fated cells to migrate 
properly [75] and in later developmental stages it plays an essential role in differentiation of all three 
muscle types [76-79]. SRF is also required for neural, craniofacial, and hematopoietic development 
[80-82].  
SRF is widely expressed, and is not exclusive to VSMC. Therefore as a regulator per se it has little 
control on VSMC phenotype shaping. The ability of SRF to adapt to particular context and respond 
adequately depends on its numerous cofactors. These belong to two protein subfamilies – ternary 
complex factors (TCFs), and myocardin protein family (myocardin (MYOCD) and myocardin-related 
transcription factors (MRTFs)). By classical view, the TCFs are effectors of MAPK signalling while 
MRTFs and MYOCD respond to Rho GTPases-actin and pro-differentiation signalling. Depending on 
cofactor availability, SRF initiates the respective gene expression program, and shifts VSMC 
phenotype accordingly. 
Among SRF cofactors, MYOCD is the most potent VSMC differentiation-driving SRF coactivator known 
to date [83]. MYOCD expression is cardiac and smooth muscle specific [84], it is irreplaceable in early 
VSMC development, and is sufficient for full VSMC differentiation – MYOCD selectively induces 
expression of all tested VSMC-specific genes containing CArG box, including MYH11, Tagln, Acta2, 
Cnn1, ion channel encoding genes Kcnmb1 and Lmod1 [56], [83]. MYOCD competes for SRF with 
growth signal activated cofactors and maintains VSMC quiescence [85]. It antagonizes KLF4 [86] and 
cyclin D1 expression [87]. MYOCD mRNA expression is downregulated in VSMC during vascular 
disorders [88], [89]. 
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In contrast to MYOCD, which is cardiac- and smooth muscle- lineage specific and unambiguously a 
pro-differentiation factor, two other myocardin family members MRTF-A and MRTF-B (also known as 
MKL1 (megakaryoblastic leukemia) and MKL2, respectively) are widely expressed and controlled by 
actin dynamics. In spite of early hypotheses suggesting myocardin substituting roles for MRTFs, it has 
now emerged that MRTFs might have context-dependent roles in VSMC phenotype regulation. Data 
on MRTF-B is quite consistent, and strongly suggests pro-differentiation role for this factor: MRTF-B is 
necessary for differentiation of cardiac neural crest cells into smooth muscle [90], remodelling of 
branchial arch arteries, smooth muscle differentiation [91], and normal VSMC-specific gene 
expression [92]. However, the role of MRTF-A is still under discussion: in one study MRTF-A 
expression in vitro induced SMC differentiation from undifferentiated embryonic stem cells [93], 
whereas and opposingly, another study found increased MRTF-A expression in the wire-injured 
femoral arteries of wild-type mice and in the atherosclerotic aortic tissues of ApoE-/- mice [94]. 
Combinatorial MYOCD, MRTF-A and MRTF-B, as well as other co-factor availability or stoichiometry 
might be of major importance for VSMC phenotype regulation too. Widely expressed protein SCAI 
(suppressor of cancer cell invasion) inhibits MRTF-A and MRTF-B activity in the cell nucleus [95]. This 
level of MRTF regulation has been discovered and investigated in the context of cancers and to date 
(2015) has not been reported to function in VSMC. SCAI involvement in VSMC phenotype modulation 
is unknown.  
4.1.2. Krüppel-like factor 4  
KLF4 plays a key role in VSMC phenotype transition during development [86], after vascular injury 
[96] , and in PDGF- or oxidized phospholipids-treated cells in vitro [97,98]. KLF4 negatively regulates 
expression of many VSMC differentiation genes, including MYH11, Acta2, Tagln and Cnn2, either by 
binding to the G/C repressor element, which is present in most of SMC-specific gene promoters, or 
by competing with SRF for CArG element binding [99,100]. KLF4 also activates pro-inflammatory 
genes; recent ChIP-seq analyses identified >800 putative KLF4 target genes in VSMC, many of which 
encode atherosclerosis relevant pro-inflammatory factors [28]. KLF4 knock-out in the atherosclerosis 
mouse model (Apo E-/-) favours acquisition of the synthetic VSMC phenotype, and suppressed the 
pro-inflammatory macrophage-like phenotype transition [28].  
4.2. Signalling pathways 
4.2.1. Pro-differentiation signalling pathways 
4.2.1.1. Rho-actin pathway 
For a long time cytoskeletal actin dynamics was seen as a passive purely structural element of the 
cell. It is now becoming clear that the cytoskeleton is also a powerful modality of signal transduction 
and gene regulation.  
Posttranslational activity of MRTFs is regulated by actin dynamics [101]. MRTFs have a globular actin 
(G-actin) binding domain (RPEL motifs), which traps these proteins in the cytoplasm, if G-actin is 
available for binding. Via regulation of effector protein activity, Rho GTPases modulate G/F (fibrillar)-
actin equilibrium. Control of G-actin availability by Rho GTPases regulates abundance of two MRTF 
states: the G-actin-bound state which is cytoplasm entrapped and inactive, and the actin-free state 
that is ready for nuclear translocation and action [102]. Actin polymerization triggered by RhoA 
liberates MRTFs from G-actin and permits their translocation to the nucleus. This type of regulation 
allows for rapid modulation of transcriptional co-activator availability, as it does not involve covalent 
protein modification and can be easily reversed. 
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It is important to note that MYOCD has no RPEL motif, and is thus independent of regulation by G-/F-
actin [103]. 
In VSMC RhoA-actin-MRTF signalling can be induced by a plethora of extracellular stimuli. Activity of 
small GTPases is regulated by guanine exchange factors (GEFs). Thrombin, sphingosine 1 phosphate 
(S1P), angiotensin II, TGF-β, BMP-2, calcium, integrins, cell tension (via integrins), matrix components 
collagen IV and laminin have been reported to induce RhoA-actin-MRTF signalling in smooth muscle 
cells [104]. 
4.2.1.2. TGF-β-Smad 
TGF-β is a multifunctional cytokine, important for blood vessel morphogenesis and stability. TGF-β 
signalling in VSMC induces differentiation and regulates cell interaction with extracellular matrix. 
TGF-β stimulates mesenchymal precursor differentiation into VSMC and the establishment of a 
functional vasculature in early development [105]. TGF-β is crucial for vessel muscularization in 
angiogenesis and regulates VSMC plasticity in mature, established vessel [106]. The importance of 
TGF-β signalling for vascular biology is illustrated by its involvement in many vascular pathologies 
including atherosclerosis, aortic aneurysms, and hypertension [107].  
Three isoforms of TGF-β are known in mammalians – TGF-β1, TGF-β2, and TGF-β3. All three are 
secreted as latent precursors. Activation via proteolytic cleavage by endoproteases is needed for 
biological function [108]. To maintain the signalling of this powerful cytokine under tight control, 
availability of active TGF-β is additionally regulated by interaction with ECM components [109] (see 
section 2.1.3.). 
When active, TGF-β binds to TGF-β type II receptor. This allows type II receptor heterodimerization 
with type I receptor. In the formed heterodimer type II receptor phosphorylates and activates type I 
receptor, a serine/threonine kinase. Active type I receptor recruits and phosphorylates Smad2 and 
Smad3. Phospho–Smad2/3 form a complex with Smad4 and translocate to the nucleus where they 
bind multiple Smad-binding elements (SBEs) and GC-rich sequences and function as transcription 
factors [110-113]. 
TGF-β signalling also regulates activity of TGF-β control elements (TCE) and CArG boxes [114]. CArG 
and TCE are often found together in many VSMC-specific marker gene promoters, including MYH11, 
Acta2, Tagln, Cnn1 [115].  
TCE in VSMC is controlled by KLF4 and Krüpel-like factor 5 (KLF5), which repress or activate VSMC 
marker expression, respectively. KLF4 acts negatively and KLF5 positively on VSMC-specific gene 
expression [116]. TGF-β stimulation inhibits KLF4 expression through miR-143/miR-145, and removes 
KLF4-mediated repression from TCE genes. In addition, KLF5 competes with KLF4, and acts 
synergistically with TGF-β in gene transcription initiation [116].  
TGF-β can also induce SRF expression and enhance its binding activity to the CArG box [117]; Smad3, 
the major mediator of TGF-β induced marker gene expression in VSMC [107], can interact with SRF 
and MYOCD and activate CArG dependent VSMC gene promoters [113,118]. 
TGF-β initiates, transactivates, or cross-talks with many other pathways to regulate VSMC plasticity in 
a context dependent manner. The best studied crosstalk examples are Smad-dependent RhoA and 
Notch signalling pathways. Dominant negative RhoA blocks Smad2 and Smad3 phosphorylation and 
impairs their nuclear translocation, while constitutively active RhoA enhances Smad-dependent 
promoter activity [119]. CBF1 (Notch-regulated transcription factor) interacts with Smad2/3 and 
enhances their transcriptional activity [120].  
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4.2.1.3. PI3K/Akt/mTOR pathway 
Insulin-like growth factor (IGF) and insulin signalling via classical PI3K-Akt pathway suppresses the de-
differentiation program in VSMC and maintains contractile phenotype [121]. Ligand activated IGF or 
insulin receptor recruits insulin receptor substrate (IRS-1) and activates it by phosphorylation on 
tyrosine residues, which provides a docking site for PI3K. Docking in close proximity to the inner 
leaflet of the plasma membrane gives PI3K physical access to its substrates, inositol phospholipids. 
PI3K converts (3,4)-bis-phosphate to phosphatidylinositol (3,4,5)-tris-phosphate (PIP3) and 
enrichment of PIP3 on the inner membrane side allows Akt binding to the membrane. At the 
membrane Akt gets activated by phosphoinositide-dependent kinase-1 (PDK1) and mTORC2. 
Phosphorylated by PDK1 only (on Tyr308) Akt is partly activated and can transmit the signal to 
mammalian target of rapamycin complex 1 (mTORC1) [122,123] [124]. Additional Akt 
phosphorylation on Ser473 by mTORC2 [125] or DNA-dependent protein kinase (DNA-PK) [126] 
stimulates full Akt activity and enables it to phosphorylate additional substrates. Fully active Akt 
regulates its downstream targets in the cytoplasm and nucleus, and represses the de-differentiation 
program in VSMC. For instance, Foxo4 phosphorylation by Akt-promotes its nuclear export and 
relieves its inhibitory influence on MYOCD activity [127].  
Direct PI3K/Akt pathway signalling is auto-regulated by the classical negative feedback loop, which is 
activated by mTORC1 through Akt. mTORC1 activates S6K, which then phosphorylates IRS-1 on serine 
residues and marks IRS-1 for proteosomal degradation. Reduced availability of IRS-1 weakens direct 
insulin and IGF signalling pathway activity [128], reducing their suppressive actions on VSMC de-
differentiation [129]. mTORC1 pathway is activated in response to vascular injury [130] and can be 
inhibited by rapamycin [131,132] or adiponectin [133]. The latter inhibits mTORC1 through AMP-
activated protein kinase (AMPK). In addition, mTORC1 inhibition stabilizes GATA-6 and favours its 
nuclear translocation; nuclear GATA-6 activates contractile protein promoters, suppresses cell 
proliferation and induces VSMC differentiation [134].  
PI3K-Akt pathway can also be activated by insulin to regulate vascular tone (see section 1.3.). 
4.2.1.4. Dual role of Notch 
Notch signalling is a conserved intercellular signalling pathway. Notch receptors and ligands are 
transmembrane proteins. Signal initiation starts when the ligand expressed on one cell binds its 
receptor located on the neighbouring cell. Ligand binding changes receptor conformation, and makes 
it accessible to proteases ADAM and γ-secretase which cleave the receptor on both sides of the 
membrane. Cleavage by γ-secretase releases Notch intracellular domain (NICD) from the membrane, 
and allows its translocation to the nucleus where it forms complex with other transcription factors 
and initiates transcription of its target genes, of which Hes and Hey, the basic helix-loop-helix (bHLH) 
proteins, are best known [135]. In VSMC Notch signalling also targets Acta2, Pdgfb and microRNA 
cluster miR143/miR-145 [136-138].  
In the vasculature Notch signalling can occur between EC and VSMC (mostly during angiogenesis), or 
through homotypic interactions between neighbouring VSMC. During development Notch 
coordinates many aspects of EC and VSMC interaction and positively regulates VSMC specification, 
differentiation and maturation [42].  
In the mature vessel VSMC express Notch1, Notch2, and Notch3 receptors and a ligand Jagged-1 
[139-142], but the role of Notch signalling for VSMC phenotype modulation is unclear. Some studies 
report Notch as a pro-differentiation pathway, the others show it as a phenotype-switch inducer: 
inactivation of Notch signalling by Notch1 or Hey2 deletion, or cell transfection with soluble Jagged-1 
reduces neointima formation and downregulates chemotaxis of isolated cells [143], [144,145], 
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deletion of Jagged-1 in EC promotes intimal and medial thickening after injury [146], and 
upregulation of both Notch and Jagged transcripts after vascular injury was reported [147].  
The fact that Notch crosstalks with both TGF-β [120] and PDGF [137], two major VSMC phenotype 
modulating signalling pathways standing on the opposite sides of the fence, suggests that both 
scenarios might be valid and the final outcome depends on particular context.  
4.2.2. De-differentiation driving signalling pathways 
Signalling by Ras-Raf-MEK-ERK pathway in VSMC is triggered by ubiquitous growth factors such as 
PDGF, epidermal growth factor (EGF) and fibroblast growth factor (FGF). 
4.2.2.1. Ras-Raf-MEK-ERK pathway 
Among growth factors and cytokines driving VSMC de-differentiation by MAPKs cascade, PDGF is 
considered to be the master [104] and an indispensable regulator of early vascular development 
[148,149]. Released from platelets at the site of tissue damage [150], PDGF stimulates growth and 
directional migration of VSMC and fibroblasts [151-153]. Further investigations in vivo showed that 
PDGF acts in VSMC mostly as a pro-migration- rather than proliferation-inducer [154,155]. PDGF is a 
disulphide-linked dimer. Its binding to the receptor causes receptor dimerization and activation. 
PDGF receptors (PDGFRs) are classical receptor tyrosine kinases (RTKs) and two known types of PDGF 
receptors, PDGFRα and PDGFRβ, homo- or hetero-dimerized, transmit the signal by classical growth 
factor regulated Ras-Raf-MEK-ERK pathway, which eventually leads to downstream phosphorylation 
and activation of TCF family proteins such as Elk1. This induces SRF-dependent transcription of early 
response growth and de-differentiation genes, and repression of smooth muscle selective markers, 
[104,156]. In addition, active extracellular signal regulated kinases (ERK) can phosphorylate MRTFs in 
the cytoplasm and prevent their translocation to the nucleus [157]. Most importantly, PDGF-BB 
induces pluripotency transcription factor KLF4, which modulates transcriptional programs of smooth 
muscle-specific genes by preventing SRF/myocardin complex to bind pro-differentiation gene 
promoters and activates promoters driving acquisition of the pro-inflammatory phenotype [88,158] 
(see section 4.1.2.). 
4.2.2.2. Other signalling pathways 
β-catenin signalling 
Elevated β-catenin and inactive GSK3β levels have been reported after vascular injury [159,160], 
[161]. Rapid cadherin junction dismantling was also reported to occur in vascular smooth muscle 
after injury [162]: this is most likely a Wnt-independent process since Frizzled receptor expression is 
downregulated in response to injury in rats [163].  
In vitro Wnt1 and Wnt3a induce β-catenin pathway and cyclin D1 expression in arterial VSMC [164], 
but the evidences for Wnt1 and 3a expression in proliferating cells or injured vasculature in vivo are 
lacking [165]. 
4.3.  Epigenetic regulators 
4.3.1. Ten-eleven-translocation 2 (TET2) 
Ten-Eleven-Translocation (TET) proteins are a family of methylcytosine dioxygenases which catalyse 
the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and perform the first 
step in DNA demethylation [166]. TET2 is highly expressed in smooth muscle and out-dominates 
other two family members (TET1 and TET3) in coronary artery SMC [167]. TET2 has been shown to be 
both necessary and sufficient for SMC differentiation in genetic loss- and gain-of-function 
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experiments. TET2 knockdown increases KLF4 expression (see section 4.1.2.), while overexpression of 
TET2 protein promotes MYOCD expression and cell differentiation [168]. In an in vivo model of 
intimal hyperplasia TET2 expression was reduced in the medial layer of injured vessels compared to 
the uninjured. Genetic loss of TET2 in the same model resulted in stronger response to injury and 
decreased H3K4me3/H3K27me3 ratio at the MYOCD, SRF, and MYH11 promoters [168]. TET2 
responds to pro-differentiation signals (e.g. rapamycin treatment) with strong binding to the 
promoters of VSMC contractile proteins [167].  
The attempts to block VSMC de-differentiation in order to prevent progression of proliferative VSMC 
disorders by targeting major signalling pathways has delivered mixed results. Anti-PDGF and 
antiplatelet therapies have been suggested and tried in restenosis patients, unfortunately with no 
substantial clinical value. Intravenous administration of humanized monoclonal antibody against 
PDGFR-β had no beneficial effects on neointimal hyperplasia after stenting [169]. Drug-eluting stents 
(DES) coated with rapamycin or other VSMC proliferation-blocking drugs have proved superior to 
bare-metal stents and revolutionised angioplasty. However, in some cases drug-eluting stenting led 
to early stent thrombosis [36]. High risk of thrombosis is at large due to DES cytotoxicity on 
endothelial cells, which impairs re-endothelialization, delays arterial healing and causes endothelial 
dysfunction in arterial areas distant from the stent. Endothelial dysfunction and prolonged wound 
healing are directly linked to increased risks of ischemia and coronary occlusion thrombosis [36]. 
Targeting major signalling pathways shared by many types of cells might deliver similar results as an 
example of rapamycin-coated stents. New, SMC-specific therapeutic strategies targeting VSMC 
unique factors and phenotype switching regulating signalling pathways are needed to achieve better 
results in treatment and prevention of SMC-linked vascular pathologies.  
N-cadherin has been proposed as a target by some research studies [170,171]. N-cadherin promotes 
VSMC migration, survival, and regulates cell polarity establishment, which is crucial step in initiation 
of migration. Blocking of N-cadherin reduces neointima growth, and shows no adverse effects on 
endothelium [170,171].  
T-cadherin could be another potential target, since its expression is upregulated during vascular 
pathologies and promotes vascular cell survival and proliferation [172,173], but is not necessary for 
basic cell functions, or vascular development (T-cadherin knock-out mice are viable and exhibit no 
obvious anatomical defects in the vasculature (unpublished observations)). Moreover, we have 
found that T-cadherin is a VSMC phenotype regulator, promoting VSMC de-differentiation 
(manuscript in preparation).  
5. Cadherins 
Cadherins are best known as Ca2+-dependent intercellular adhesion receptors which mediate 
homotypic cell-cell cohesion to organize functional tissues [174]. Alongside with this function 
cadherins have “non-canonical”, adhesion-independent functions, which can be observed in a single 
cell.  
Most of the knowledge on cadherins comes from studies on classical cadherins. However, this type of 
cadherins constitute only a small fraction of a large and structurally diverse cadherin superfamily 
(110 members at least [175,176]), strongly suggesting that the functions fulfilled by cadherins might 
be numerous and varied.  
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5.1. Classification and structure 
The cadherin superfamily consists of proteins containing cadherin-like domain. All known cadherins 
are classified into 6 subfamilies: type I (classical, adherens junctions forming cadherins), type II, 
desmosomal (found in desmosomal junctions), protocadherins, 7D cadherins and atypical cadherins 
[177]. Classical cadherins are the best studied cadherins of the superfamily, mostly in the contexts of 
development and cancer. Classical cadherins are composed of three major structural domains – 
extracellular, single-pass transmembrane and intracellular. The extracellular (EC) domain of classical 
cadherins consists of five EC Ca2+ binding repeats. Ca2+ is indispensable for cadherin function: Ca2+ 
binding shapes cadherin into active conformations and enables homophilic cadherin dimerization in 
trans (between identical cadherins on adjacent cell), as well as lateral cadherin clustering in cis to 
assemble zipper-like structure. The intracellular domain contains armadillo domains – conservative 
sites which binds β-, or p120-catenin. β- and 120-catenins bind α-catenin and integrate adherens 
junctions into the cell’s actin cytoskeleton [177]. Cytoskeleton-bound cadherin clusters between the 
adjacent cells are called adherens junctions (AJs). AJs serve structural function as physical bonds, as 
well as cell-cell communication/signalling hubs. 
5.2. Cadherin functions 
5.2.1. Adherens junctions 
As a structural component of intercellular adhesion, AJs have inherent selectivity. Cadherin binding in 
AJs is strictly homophilic, and therefore occurs only between the cells expressing the same type of 
cadherins. Since different cell types express different sets of cadherins, homophilic binding ensures 
the selectivity and proper positioning of connected cells that is crucial for establishment of proper 
 
Fig.4. Schematic structural overview of representative members of the cadherin superfamily. The following 
protein domains are annotated: CBD (conserved β-catenin/plakoglobin-binding domain); UCD (unique 
cytoplasmic domain); CE (cysteine-rich EGF-repeat-like domain); CM1, CM2 and CM3 conserved motifs in the 
CDs of δ-PCDHs; EC1 to EC34 (extracellular cadherin repeats); GPI (glycosylphosphatidylinositol anchor); JMD 
(conserved juxtamembrane domain required for p120‑catenin binding); LAG (laminin-A globular domain-like 
domain); MLD (mucin-like domain); Pro-d (prodomain); RUD (intracellular repeated unit domain of 
desmosomal cadherins).Adapted from [177]. 
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tissue architecture [178]. Classical cadherins therefore are indispensable in early development, when 
primary tissues start to develop and segregate [174,179]. In the central nervous system adhesion 
complexes formed by cadherins play key roles in synapse formation and plasticity [180]. Here 
cadherins have dual roles. Some cadherins function as positive synapse guiding cues, while the 
others do negative guidance. For example, OB-cadherin signals as a positive guide [181], while T-
cadherin is a negative axon guidance providing molecule [182]. 
5.2.2. Cell communication – polarity 
Physical cell binding strength and polarity are key factors controlling differentiated cell behaviour 
such as polarization and migration [183,184], or stem cell fate decisions [185]. As the organizers of 
cell-cell contact formations cadherins play key roles in cell polarity establishment and cell guidance.  
AJs are anchored to the cytoskeleton and therefore form local barriers in the cell membrane which 
limit free lateral floating of membrane proteins and contribute largely to establishment of membrane 
heterogeneity and cell polarity [186]. Cadherin binding to catenins via the intracellular cadherin 
domain immobilizes catenins to the membrane. This not only restricts the nuclear function of 
catenin, but also polarizes the cell biochemically since at the membrane catenins function as 
scaffolding proteins and recruit important elements of spatiotemporal signalling to the cell 
membrane [187]. In addition, classical AJs initiate tight junction formation [188], the key factor for 
cell polarity establishment.  
Cell polarization in response to migration cues (seen as displacement of the nucleus toward the cell-
cell contact and of cell migratory machinery away from it, and prepares the cell for coordinated 
movement) is a cadherin guided process [189]. Asymmetries in cell-cell adhesion, which can occur 
due to injury or the cadherin switch during the classical epithelial-to-mesenchymal transition (EMT), 
result in cell (re)polarization and migration. Cell division control protein 42 (Cdc42)-dependent 
cadherin signalling at the cell-cell border plays a primary role for cell polarization in disrupted cell 
monolayers [189,190]. In classical EMT, E-cadherin replacement by N-cadherin (the cadherin switch) 
blocks contact inhibition of locomotion (CIL) and initiates cell (re)polarisation [183]. Interestingly, 
although both cadherins are classical cadherins and are known to form AJs, E-cadherin re-expression 
in migratory cells restores CIL, while E-cadherin depletion or switch to the N-cadherin expression 
promotes cell polarization and induces directional migration [183]. Similar cadherin competition is 
observed between N-cadherin and VE-cadherin in EC [177]. VE-cadherin inhibits EC growth, migration 
and apoptosis by suppression of vascular endothelial growth factor receptor 2 (VEGFR2)/ERK 
signalling and induction of TGF-β/SMAD signalling [191], while N-cadherin functions as a pro-
migratory protein [192]. VE-cadherin seems to have higher hierarchy in this context, since N-cadherin 
expression can be suppressed by VE-cadherin [192].  
To date true mechanistic explanations for cadherin switch are lacking. Pure chemoaffinity differences 
between E- and N- cadherins do not explain the switch since homophilic N-cadherin ligation is 
stronger than that of homophilic E-cadherin ligation [193]. It has been suggested that E-cadherin 
replacement by N-cadherin enables epithelial cells to adhere to mesenchymal cells and invade the 
stroma expressing different types of cadherins [177]. Preferential OB-cadherin (osteoblast cadherin)-
positive prostate cancer metastasis to the bone supports this theory [194]. Other authors suggest 
that the intercellular cadherin domain rather than extracellular domain is most important for CIL 
inactivation during the cadherin switch [183]. Earlier cadherin studies demonstrated that AJs formed 
by cadherins lacking β-catenin binding sites display weaker adhesions than native cadherins [195]. 
Since β-catenin functions as a scaffolding protein in AJs, differences in the C-terminal cadherin 
domains of E- and N-cadherin might result in formation of distinct multiprotein complexes and 
modulate intercellular adhesion properties, which might further affect cell behaviour. In addition, 
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homophilic adhesion-independent individual cadherin functions might be equally important in the 
cadherin switch. N-cadherin, for example, can activate fibroblast growth factor receptor 1 (FGFR1) 
signalling and induce EMT in a cell autonomous manner [196,197]. Finally, the biological context in 
which the cadherin switch takes place is no less important. In contrast to epithelial cells undergoing 
EMT, migrating VSMC display strong CIL when encountering N-cadherin expressing cells [170], which 
suggests complex tissue and biological context specific hierarchy between classical cadherins. 
The cadherin switch phenomenon perfectly illustrates the multi-modality of cadherins and 
complexity of cadherin-mediated intercellular communication, suggesting the existence of a 
“cadherin code” which enables the cell to adopt multiple behavioural modes in order to adapt to 
various biological contexts. 
5.2.3. Mechanotransduction 
Due to the binding strength and direct connections to the cytoskeleton AJs are well suited to function 
as mechanotransducers (mechanosensors and mechanoresponders) [198-200]. In smooth muscle 
this type of communication is especially important, since well-coordinated collective cell contraction 
is essential for proper smooth muscle function. Upon mechanical stimulation N-cadherin strengthens 
connections between load-affected SMC and facilitates intracellular transition of contractile force 
[198,201]. Desmosomal cadherins, which mediate intercellular adhesion in desmosomes, recruit 
desmoplakin and intermediate filaments through plakophilins and plakoglobins, thereby rendering 
desmosomes tension-resistant [1]. In addition, VE-cadherin participates as an adaptor in 
mechanosensor complex formation between platelet endothelial cell adhesion molecule (PECAM) 
and VEGFR2, and facilitates activation of nuclear factor-κB [199].  
5.2.4. Cell autonomous functions. Vesicle closure and cell transport 
Adhesion dependent functions of N- and E-cadherin can be observed in a single cell. In a cell 
autonomous mode of function, classical cadherin-mediated adhesion helps to close back folding 
membrane ruffles and form macropinosomes [202].  
5.2.5. Signal transduction 
5.2.5.1.  PI3K signalling 
Intercellular communication and cell-matrix adhesion are vital for pro-survival stimulus and cell 
escape from apoptosis. In VSMC intercellular adhesion is as important as cell anchorage to the matrix 
for cell survival[203]. Mechanistically this is achieved via PI3K-Akt signalling: cadherin-catenin 
complex formation activates PI3K-Akt cascade and blocks “default” cell apoptosis by inactivation of 
pro-apoptotic protein Bad (Bcl-2 antagonist of cell death) and stabilization of anti-apoptotic factor 
Bcl-2 (B-cell lymphoma 2) [171,204-207].  
5.2.5.2. β-catenin and canonical Wnt signalling 
The key element in the canonical Wnt pathway is β-catenin, a multifunctional protein which can act 
either as a structural and scaffolding protein that stabilizes cell-cell junctions, or as a transcription 
coactivator in the nucleus. Cadherin-bound, cell membrane localized β-catenin functions as a 
structural component of the intercellular adhesome, while in the nucleus it participates actively in 
gene expression control [208]. Classical cadherins are therefore considered direct negative regulators 
of β-catenin signalling [208]. Dismantling of AJs and accumulation of free β-catenin can occur due to 
the initiation of developmental programs, cancerous cell transformation or tissue injury. Nuclear β-
catenin translocation during developmental processes and cancer is usually initiated by Wnt 
signalling, while injury-induced β-catenin signalling is part of repair mechanisms.  
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Wnt family members are secreted proteins that coordinate cell-cell interaction during embryonic 
development and adult tissue homeostasis [209]. Wnt proteins bind Frizzled family receptors and 
activate canonical Wnt signalling pathway. Canonical Wnt pathway signalling via T-cell 
factor/lymphoid enhancer factor (TCF/LEF) transcription factors controls morphogenesis and cell fate 
regulating gene expression programs [210]. In quiescent cells, β-catenin is locked in cellular junctions 
and free β-catenin is kept under strict control by the degradation complex consisting of scaffolding 
protein axin, GSK3β, casein kinase 1 (CK1), and the adenomatous polyposis coli (APC). However, in 
response to Wnt signalling through its receptor Frizzled, the degradation complex undergoes 
rearrangement and switches to the inactivate state. GSK3β becomes inactivated and can no longer 
phosphorylate β-catenin and direct it for degradation. Accumulating β-catenin translocates to the 
nucleus and initiates its target gene transcription. Most of the β-catenin/TCF/LEF target genes are 
cell type specific [209]. Importantly, β-catenin nuclear function can be initiated by mechanisms 
independent of Wnt. Free β-catenin can be stabilized by changes in cadherin abundance or cellular 
distribution. This can result in Wnt-independent β-catenin signalling, or heighten Wnt responses. 
Mutations disabling β-catenin binding to cadherins are often accompanied by higher β-catenin 
nuclear activity, which can lead to cancerous transformation of the cell. Recurrent cadherin-related 
protein Fat1 mutations together with increased β-catenin nuclear function have been reported in 
glioblastoma, colorectal cancer, and head and neck cancer [211]. 
In the vasculature β-catenin signalling is most relevant to injury repair. Elevated β-catenin and 
inactive GSK3β levels have been reported after vascular injury to the endothelium [159], [160], [161]. 
T-cadherin upregulation in endothelial cells leads to integrin-linked kinase mediated GSK3β 
inactivation, β-catenin stabilization, and TCF/LEF-dependent cyclin D1 induction [212]. Rapid AJs 
dismantling and accumulation of β-catenin has been shown to take place in vascular smooth muscle 
after injury [162]. MMP-9 and -12 dependent shedding of the extracellular N-cadherin domain 
elevates VSMC proliferation via β-catenin signalling [213]. 
 
5.2.5.4. Growth factor signalling modulation 
Cadherins can interact with other types of adhesion molecules and form heterophilic interactions 
outside of the cadherin family [214], or even with non-adhesion molecules (e.g. growth factor 
receptors), and modulate their signalling. As already mentioned, N-cadherin binds FGFR1 in cis and 
prevents ligand-induced receptor internalization, which leads to sustained receptor signalling 
[197,215,216]. Similarly P-cadherin binding to IGF receptor 1 (IGFR1) induces ligand-independent 
receptor signalling and activates cytoplasmic p120-catenin. Active p120-catenin promotes cell 
migration [217]. Non-classical cadherin-17 interacts with α2β1 integrin heterodimer and activates β1 
integrin. This leads to FAK, Ras and Jun N-terminal kinase activation, and stronger adhesion to 
collagen IV [218]. In squamous cell carcinoma cells T-cadherin can supress EGFR signalling, cell cycle 
progression and cell migration [219]. In EC, T-cadherin directly interacts with IR (insulin receptor), 
effectively highjack IR signalling effectors and thereby cause insulin resistance by amplifying the 
negative feedback look of mTORCs/S6K1-mediated serine phosphorylation and degradation of IRS-1 
[220]. 
5.2.5.5. Cleaved cadherin signalling 
Proteolytically cleaved intracellular or extracellular cadherin domains can have independent 
functions and act as separate signalling elements. For example, N-cadherin cleavage by ADAM10 
generates a cytoplasmic fragment which strengthens β-catenin nuclear signalling [221], and MMPs 
cleave P-cadherin to release extracellular cadherin domain which functions as pro-migratory factor 
[222].  
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Cadherin flexibility in adhesion partner selection, combined with multi-domain organization equips 
these molecules with flexible specificities, and makes them adaptable for many biological contexts 
[188].  
5.2.5.6. YES/YAP and Hippo pathway 
Hippo pathway regulates organ growth, stem cell function, and regeneration via activity control of 
transcription tandem YES associated protein (YAP) and TAZ [223]. YAP/TAZ are transcription co-
activators which promote cell proliferation and inhibit cell death. Hippo pathway represses YAP/TAZ 
activity. 
E-cadherin, α-catenin and other structural AJ proteins can sequester YAP/TAZ to the junctions and 
repress their nuclear function directly [224], or via activation of Hippo pathway [223].  
5.2.5.7. Receptor function 
T-cadherin is a third adiponectin receptor which specifically binds hexameric and high molecular 
weight adiponectin [225]. T-cadherin binding localizes adiponectin to the endothelium and promotes 
revascularization [226]. T-cadherin also binds low density lipoproteins (LDL) [227] with proposed 
functionality as a signalling receptor for LDL that facilitates LDL-dependent mitogenic signalling in the 
vasculature [228,229]. 
5.3. Cadherins in vascular smooth muscle 
VSMC express a number of cadherins. N-cadherin, T-cadherin, OB-cadherin, 6B-cadherin [230], R-
cadherin, E-cadherin and Fat1-cadherin expression have thus far been reported. Although most of 
these cadherins have been very poorly studied in vascular smooth muscle, existing data suggests that 
different subsets of cadherins may be expressed by different SMC subpopulations within the vessel 
wall, and that mechanisms similar to cadherin switching in EMT might play important roles in SMC 
phenotype modulation. SMC in vivo are surrounded by high contents of ECM [1], and cadherins with 
Table 1. Cadherin functions 
Function Cadherin Reference 
Adherens junction formation Classical cadherins 174, 177, 178-182  
Tight junction formation Classical  181, 188 
Synapse formation Classical, OB, T 177, 188, 250 
Cell polarity regulation N, E, P  183, 189, 192 
Vesicle closure N, E 202 
Mechanotransduction N, VE 198-201 
Signal transduction   
Classical PI3K pathway N 171, 204-207 
β-catenin/ canonical Wnt E, N, (other classical), T 174, 177, 188, 211-213, 221 
Growth factor signalling 
modulation 
N-FGFR1 197, 214-216 
 P-IGFR1 217 
 Cdh17-α2β1 218 
 T-EGFR 219 
 T-IR 220 
Hippo pathway (activation) E (possibly other 
classical AJ forming) 
223, 224 
Receptor T-Adiponectin 225 
 T-LDL 227 
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extracellular domains of different lengths might be needed to reach between the cells. AJs and 
desmosomes have been demonstrated in large and small arteries in vivo [231]. Cadherin involvement 
in organizing correct arterial tissue architecture is therefore doubtless.  
5.3.1. N-cadherin 
N-cadherin is a major classical cadherin in VSMC. Despite its abundance relatively little is known 
about N-cadherin functions in the vasculature [232]. So far two major modes of adhesion-dependent 
functions have been reported, namely formation of AJs and assistance in micropinosome closure. 
The later function is cell autonomous, but still relies on classical homophilic cadherin ligation. AJ-
independent N-cadherin functions in VSMC includes pro-survival signalling, and migration initiation. 
Correct intercellular adhesion is crucial for early development of the cardiovascular system. Full and 
endothelium-specific N-cadherin knock-out is lethal. Cardiomyocytes of N-cadherin knock-out mouse 
fail to form proper gap junctions, which leads to cardiac arrhythmias and embryo death at E10.5 
[233,234] – the developmental stage when cardiac activity and vessel perfusion starts. Vascular EC-
specific N-cadherin knock-out embryos die of severe oedema (unstable and leaky vessels) also at 
E10.5 [235]. In this case EC lacking N-cadherin are still able to form ordinary tubules, but fail to 
muscularize properly (by connecting to VSMC or pericytes) and stabilize the vessel [236,237]. This 
suggests that proper adhesion between EC can be formed in the absence of N-cadherin, but for the 
establishment of stable contacts between EC and VSMC N-cadherin is indispensable. 
In adult vessel AJs formed by N-cadherin are needed for collective VSMC contraction [238] and 
proper regulation of arteriolar myogenic tone [232]. Upon contractile activation β-catenin is 
recruited to N-cadherin. This strengthens existing, or forms new AJs between adjacent cells and 
facilitates intracellular transition of contractile force, orchestrating collective cell contraction 
[198,201]; N-cadherin blockade in the rat arteriole reduces myogenic response to intravascular 
pressure [239].  
N-cadherin also plays a part in vascular regeneration and repair. Vascular injury promotes rapid 
disassembly of cellular adhesions and downregulation of N-cadherin expression. In the absence of N-
cadherin, β-catenin can translocate to the nucleus and induce cell proliferation [162,213]. At later 
stages of vessel healing (1 week after injury) N-cadherin expression is restored and upregulated. Here 
N-cadherin seems to function in a cell adhesion-independent mode and induces directional cell 
migration to the intima: in the migrating cell N-cadherin is localized to the leading cell edges 
(lamellipodia) or to growth factor induced dorsal membrane ruffles [202,240-242]. In the leading 
edge N-cadherin forms strong connective ligations between closely located membranes promoting 
macropinosome closure and liquid phase uptake [202], both of which are needed for cell motility and 
quick (migrational) cell polarity establishment [170]. N-cadherin also activates PI3K-Akt signalling to 
block pro-apoptotic protein Bad and inhibit cell apoptosis [171,205,206].  
Pro-survival signalling can be regulated by N-cadherin in a positive manner through initiation of 
ligand-free FGFR signalling [197,243] in a negative manner via TCF/LEF-dependent β-catenin 
signalling [159].  
5.3.2. E-cadherin, R-cadherin, FAT1, OB-cadherin 
Expression of E-cadherin within human atherosclerotic lesions was described, although not on SMC 
[244]. Expression of E-cadherin on SMC in vitro and its downregulation in response to oxidized LDL 
has also been reported [245]. Studies on R-, FAT1- and E-cadherin in the context of SMC are very 
rare. Downregulation of R-cadherin occurs during early experimental restenosis and in association 
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with increased SMC proliferation [246], while FAT1 expression increases [247]. In vitro FAT1 
stimulates SMC migration, but inhibits proliferation [247]. In SMC FAT1 localizes to both cell-cell 
junctions and cell free edges; cell-cell localization might limit SMC proliferation, while presence at 
cell free edges may signal directional migration cues during vascular remodelling [247]. In vitro cell 
collectivization experiments showed that OB-cadherin cooperates with N-cadherin and forms hybrid 
AJs [248]. Blocking either of OB- or N-cadherins inhibited AJ formation and cell collectivization. This 
type of cell collectivization was mediated via TGF-β-OB-cadherin dependent adhesive switching 
[248].  
Contributions of E- R-, FAT1-, and OB- cadherins to SMC phenotype control have not been studied.  
5.3.3. T-cadherin 
T-cadherin is an atypical cadherin. In contrast to classical cadherins, T-cadherin lacks transmembrane 
and intracellular domains as well as the HAV motif in the extracellular cadherin repeat, all of which 
are crucial for stable homophilic adhesion and 
signal transduction by classical cadherins (Fig.5.). 
Nevertheless, T-cadherin is phylogenetically closest 
cadherin to the classical cadherins, sharing high 
sequence similarity [249]. Instead of intracellular 
domain T-cadherin is bound to the membrane via 
GPI-anchor, and therefore has no direct 
connection with the cytoskeleton and is unlikely to 
function as a AJs forming protein. Although GPI-
anchoring does not provide connection to the cell 
cytoskeleton, it serves as a ligand binding site. – T-
cadherin is a receptor for LDL [227] and a third 
receptor for adiponectin [225] (see section 
5.2.5.7.). Adiponectin binding region in T-cadherin 
molecule is however still unknown. T-cadherin 
localizes adiponectin to the vasculature and 
activates proangiogenic revascularisation [226]. 
Studies to date reported functional T-cadherin 
involvement in nervous system, vasculature and 
cancer. In nervous system T-cadherin participates 
in neurodevelopment and synapse plasticity by 
guiding axon outgrowth [182] and regulating 
negatively inhibitory synapses [250]. In cancer T-
cadherin can have tumour promoting or 
suppressing role, where the final outcome seems 
to be context dependent [251].  
In the vasculature T-cadherin is expressed on EC, VSMC and pericytes, but not on fibroblasts or 
periaortic adipose tissue [172,252]. It is also strongly expressed on cardiomyocytes [172,253], and 
therefore is sometimes called H-cadherin (heart cadherin), its functions in the cardiomyocte have not 
been studied. In EC T-cadherin is upregulated during atherosclerosis and restenosis and functions as 
a cell resistance factor to oxidative stress, endoplasmic reticulum stress, hyperglycemia and 
hyperinsulinemia [172,254-256]. It regulates cell motility, proliferation, promotes survival, 
angiogenesis and revascularization [173,226,251,257], and can also attenuate insulin-dependent 
signalling [220]. To regulate these processes in EC, T-cadherin signals via the PI3K-Akt signalling axis, 
 
Fig.5. Atypical structure of T-cadherin. In 
contrast to classical cadherins (left), T-cadherin 
(truncated) lacks transmembrane and 
intracellular domains as well as the HAV motif in 
the first extracellular cadherin repeat, all of 
which are crucial for stable homophilic adhesion 
and signal transduction by classical cadherins. 
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β-catenin and small RhoGTPases [212,220,258], and utilizes a variety of molecular adaptors (insulin 
receptor, Grp78, integrin linked kinase and integrinβ3) [220,255,259] that can be recruited to lipid 
raft domains of the plasma membrane where T-cad locates [260]. 
T-cadherin functions in vascular smooth muscle are largely unknown. As in the endothelium, on 
VSMC T-cadherin expression is increased at all stages of atherosclerosis and during the early 
(proliferative) phase of experimental restenosis. Moreover in the muscle layer its expression pattern 
correlates negatively with SM-α-actin expression [172,252,261,262]. In vitro T-cadherin expression 
follows cell cycle progression [263] and ectopic overexpression of T-cadherin promotes proliferation 
[173,264]. In response to migration stimuli T-cadherin redistributes from its resting, global cell body 
location to the leading edges of the cell, and plating VSMC on recombinant T-cadherin-coated 
substratum reduces cell spreading and cell adhesion [173].  
Taken together, these data suggest that in VSMC, as in neurons, T-cadherin might have functions in 
homophilic interaction-dependent cellular guidance and regulation of the cellular adhesome.  
Studies in this dissertation are aimed at establishing cellular functions for T-cadherin in VSMC 
contraction and phenotype plasticity and identifying mediating molecular mechanisms. 
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DISSERTATION OBJECTIVES 
My dissertation comprises two studies. A very brief background together with the major objective 
and research plan for each of the studies are outlined below, followed thereafter by presentation of 
the resultant manuscripts. 
1. T-cadherin modulates VSMC sensitivity to insulin 
In vasculature insulins functions reach beyond the metabolic control. Insulin signalling via PI3K 
maintains SMC quiescence, neutralizes the de-differentiation-driving PDGF signalling, and regulates 
SMC contraction dynamics. Recent studies demonstrated that T-cadherin upregulation on EC 
promotes a state of cellular insulin resistance. T-cadherin blunts EC sensitivity to insulin by hijacking 
receptor and downstream effectors of the PI3K pathway of insulin. Immunohistochemical studies 
showed that T-cadherin expression on SMC is upregulated in pathological conditions (e.g. 
atherosclerosis) related to insulin resistance. Our preliminary experiments in vitro confirmed these 
observations and showed that the phenomenon can be simulated in vitro: SMC culturing under 
conditions mimicking hyperinsulinemia or hyperglycemia leads to upregulation of T-cadherin 
expression. What consequences T-cadherin upregulation has on insulin signalling and smooth muscle 
contractile function is unknown. 
OBJECTIVE 
To establish whether T-cadherin affects constitutive and insulin-induced Akt/mTOR axis signalling 
and contractile competence of SMC. 
RESEARCH PLAN 
1. To investigate how alterations of T-cadherin expression impact constitutive and insulin-
induced Akt/mTOR axis signalling  
1.1. Examine constitutive Akt/mTOR signalling in SMC with elevated T-cadherin expression;  
1.2. Examine insulin induced Akt/mTOR signalling in SMC with elevated T-cadherin 
expression; 
1.3. Define and compare IRS-1: pIRS-1Ser636/639 ratio.  
2. To investigate how elevated T-cadherin expression impacts SMC contractile competence 
2.1. Examine constitutive and insulin conditioned phosphorylation status of myosin light 
chain phosphatase regulatory targeting subunit MYPT1, myosin light chain MLC, and 
iNOS expression; 
2.2. Examine constitutive and insulin-induced activity of small Rho GTPase RhoA; 
2.3. Examine SMC behaviour in 3D-collagen gel; contractile competence and/or matrix 
reorganization. 
The findings of this project have been published (see pages 35-46). 
Frismantiene, A., Pfaff, D., Frachet, A., Coen, M., Joshi, M.B., Maslova, K., Bochaton-Piallat, M.L., 
Erne, P., Resink, T.J., and Philippova, M. 2014. Regulation of contractile signaling and matrix 
remodeling by T-cadherin in vascular smooth muscle cells: Constitutive and insulin-dependent 
effects. Cell Signal 126:1897-1908 
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2. T-cadherin induces VSMC phenotype switch 
SMC exhibit high degree of cellular plasticity. On demand guided by environmental cues fully 
differentiated SMC de-differentiate and re-enter cell cycle. De-differentiating SMC lose contractile 
properties, start to produce ECM proteins, proliferate rapidly and gain the ability to migrate. In a 
healthy vascular wall individual SMC de-differentiation occurs at a low event rate and ensures 
constant vascular wall renewal, or in case of injury, damaged tissue repair. However, when 
phenotype transition controlling mechanisms fail, SMC plasticity contributes to life threatening 
conditions like atherosclerosis, restenosis or graft failure. Despite high demand for improved 
cardiovascular therapeutics and intense research, mechanistic pathways controlling SMC phenotype 
switch remain poorly understood.  
Previous work in our laboratory showed that T-cadherin is expressed on SMC and undergoes 
upregulation in vivo during atherosclerosis and restenosis. In atherosclerotic lesions T-cadherin 
expression negatively correlates with SM-α-actin expression. In vitro proliferating SMC express higher 
T-cadherin levels than quiescent cells, and ectopic upregulation of T-cadherin in vitro causes insulin 
resistance and induces matrix remodelling (outcome of project 1 above). All these findings indirectly 
suggest that T-cadherin might play an important role in SMC phenotype plasticity. Whether and how 
T-cadherin regulates SMC plasticity and signalling mechanisms underlying such regulation have never 
been formally investigated. 
OBJECTIVE 
To define functional and molecular SMC characteristics regulated by T-cadherin and establish a role 
for this molecule in control of SMC phenotypic modulation. 
RESEARCH PLAN 
1. To define T-cadherin’s role in SMC phenotype transition in vitro. 
1.1. Characterize SMC morphology;  
1.2. Investigate whether ectopic dosage of T-cadherin also results in alteration of SMC-
specific marker expression; 
1.3. Investigate whether changes in T-cadherin expression affect SMC migration and 
proliferation. 
2. To identify signalling pathway(s) utilized by T-cadherin to promote SMC phenotype transition 
2.1. Examine classical SMC phenotype transition regulating signalling pathways Ras/Raf-
MEK/Erk, and p38 signalling; 
2.2. Examine GSK3β-β-catenin signalling pathway; 
2.3. Examine MRTF signalling pathway; 
2.4. Verify identified target pathway with functional assays. 
The findings of this project have been published (see pages 47-61). 
Frismantiene, A., Dasen, B., Pfaff, D., Erne, P., Resink, T.J., Philippova, M. 2016. T-cadherin promotes 
vascular smooth muscle cell dedifferentiation via a GSK3β-inactivation dependent mechanism. Cell 
Signal 28(2016):516-530.  
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CONCLUSIONS and FUTURE PERSPECTIVES 
Conclusions 
Collectively, the studies undertaken in this thesis contribute to a better understanding of cadherin 
involvement in regulation of fundamental SMC functions – contractility and ability to switch 
phenotype. We found that T-cadherin, an atypical member of cadherin family, regulates intrinsic 
VSMC contractile competence, responsiveness to insulin and promotes matrix remodelling. 
Moreover, our studies demonstrate that this molecule also regulates VSMC phenotype switch and 
promotes transition to the de-differentiated phenotype.  
While VSMC de-differentiation is crucial for tissue regeneration and reparation, faulty control of 
transition with failure to either maintain or regain the differentiated contractile phenotype underlies 
development of vascular pathologies. The knowledge gained in the course of this dissertation reveals 
a completely novel aspect of cadherin-based cellular and molecular mechanisms that can participate 
in VSMC phenotype transition processes and is relevant for the search of new therapeutic tools and 
strategies to treat VSMC-driven vascular pathologies. Importantly, our findings position T-cadherin as 
a potential target molecule in prevention of adverse vessel remodelling and SMC de-differentiation. 
Although not presented here, our preliminary investigations on vascular tissues from T-cadherin 
knock-out mice failed to identify any anatomical vascular defects in these mice. This might suggest 
that T-cadherin functions primarily as a regeneration factor and is dispensable in vasculogenesis, and 
would reinforce our in vitro findings with T-cadherin-deficient VSMC as reported in this dissertation.  
We established here that the shift in functions which T-cadherin induces in VSMC is achieved via 
modulation of Akt/mTOR and Akt/GSK3β signalling: hyperactivation of the classical PI3K/Akt 
signalling core heightens negative mTORC1/S6K feedback, and inactivates GSK3β. On one hand this 
leads to elevated IRS-1 degradation and blunted insulin response, and on the other hand it stabilizes 
cyclin D1 via GSK3β inactivation which promotes cell cycle progression and cell proliferation. 
Although we did not specifically address the interaction between the separate branches of PI3K/Akt 
signalling (mTORC1/S6K and GSK3β/cyclin D1), cooperation between them in our model is very likely, 
as has been shown by many other studies investigating classical PI3K/Akt signalling. Our findings 
suggest the existence of tight mechanistic links between cellular insulin resistance, matrix 
remodelling and phenotype transition.  
Perspectives 
The following briefly outlines some of many issues regarding the regulation of VSMC function and 
phenotype by T-cadherin that could be addressed in future investigations. Key topics are indicated in 
italicized and underlined font. 
GSK3β-inactivation stabilized both cyclin D1 and β-catenin. Although β-catenin can transcriptionally 
regulate cyclin D1 levels, here we found that β-catenin accumulation does not link to TCF/LEF binding 
and activation of de novo cyclin D1 transcription. Furthermore, upregulated β-catenin did not show 
TCF/LEF binding, and the functional role of β-catenin in T-cadherin-induced VSMC de-differentiation 
remains unknown. Further studies are needed to address this question in VSMC.  
PI3K/Akt pathway is central for T-cadherin signalling in VSMC, however, upstream partners of T-
cadherin signalling remain unknown. How T-cadherin regulates the PI3K/Akt signalling axis and 
whether its activation is a primary or subsequent event in the phenotype transition-initiating cascade 
have not yet been investigated.  
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A further set of data obtained during the course of this dissertation shows that T-cadherin also 
regulates cellular adhesion: T-cadherin overexpressing VSMC display defective cell spreading and 
reduced cell-to-matrix adhesion together with a distinct actin cytoskeleton organization. This is 
consistent with our previous findings in EC and prostate cancer cells, both of which also exhibit T-
cadherin-dependent alterations in morphological characteristics. T-cadherin overexpression also 
reduced general activity of small RhoGTPases – RhoA, Rac1, and Cdc42 in resting cells. RhoGTPases 
are powerful regulators of adhesion and cytoskeleton dynamics. Reduced activity of all three 
proteins suggests involvement of some important upstream regulator(s) in T-cadherin signalling, 
possibly components of the integrin adhesome. Indeed, in EC we have demonstrated physical 
interactions of T-cadherin with β3 integrin and integrin linked kinase. Through an ability to modulate 
cell-matrix adhesion T-cadherin might regulate different aspects of cell behaviour, including cell 
motility, polarity, growth, and survival. This suggest clear directions for further studies aimed to 
identify immediate molecular partners in T-cadherin signalling, as well as possible cadherin role in 
regulation of cell-matrix adhesion.  
The research presented in this dissertation established cellular functions for T-cadherin in VSMC 
contraction and phenotype plasticity and identified molecular mechanisms mediating T-cadherin 
signalling. Most of the study, however, has been undertaken using in vitro models. The T-cadherin 
knock-out mice (Cdh13−/−) is viable and appear anatomically normal. Validation of our findings 
through use of (Cdh13−/−) mice would add further value to the existing data; experimentation 
designed to microscopically/immunohistologically study the vasculature could be performed, or in 
vitro experimentation using VSMC isolates (and eventually “rescue” experiment using vectors 
carrying human or murine T-cadherin). In addition, Cdh13−/−mice challenge experiments (e.g. carotid 
artery balloon injury) or generation of double knock-out for T-cadherin and Apo E (apoE−/− /Cdh13−/−) 
would be instrumental in scrutinizing the most relevant biological contexts (e.g. atherosclerosis, 
restenosis) for T-cadherin functions in vascular smooth muscle.  
Another interesting question directly related to T-cadherin signalling in VSMC, but not addressed in 
this study is the involvement of adiponectin. T-cadherin is a third adiponectin receptor, which locates 
adiponectin to the vasculature. How presence of adiponectin might alter T-cadherin signalling and 
what consequences for VSMC functions this can have, remains to be determined. 
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5mC, 5 methylcytosine  
5hmC, 5 hydroxymethylcytosine 
AJs, adherens junctions 
AMPK, AMP-activated protein kinase 
APC, adenomatous polyposis coli 
ApoE-/-, ApoE-deficient mouse model 
bHLH, basic helix-loop-helix  
Bad, Bcl-2 associated death promoter  
Bcl-2, B-cell lymphoma 2 
BMP, bone morphogenetic protein 
CAD, coronary artery diseases  
CADASIL, Ccerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy 
CArG-box, CC[A/T]6GG motif 
Cdc42, cell division control protein 42 
CIL, contact inhibition of locomotion 
CK1, casein kinase 1 
CVD, cardiovascular disease  
DES, drug-eluting stent 
EC, endothelial cell 
EC, extracellular 
ECM, extracellular matrix 
EGF, epidermal growth factor 
EMT, epithelial-to-mesenchymal transition 
eNOS, endothelial nitric oxide synthase  
ERK, extracellular signal regulated kinases 
F-actin, fibrillary actin 
FGF, fibroblast growth factor 
FGFR1, FGF receptor 1 
G-actin, globular actin 
GEF, guanine exchange factors 
hES-MCs, human embryonic stem cell-derived mesenchymal cells 
IGF, insulin-like growth factor 
IGFR1, Insulin-like growth factor receptor 1 
iNOS, inducible nitric oxide synthase  
IR, insulin receptor 
IGF, insulin-like growth factor 
IGFR1, IGF receptor 1 
IRS-1, insulin receptor substrate 
KLF4, Krüppel-like factor 4 
KLF5, Krüppel-like factor 5 
LDL, low density lipoprotein 
MAPK, mitogen activated protein kinase(s) 
MKL1/2, megakaryoblastic leukemia 1 and 2 
MLC20, 20 kDa myosin light chain  
MLCK, myosin light chain kinase 
MLCP, myosin light chain phosphatase 
MMP, matrix metalloproteinase 
MRTF, myocardin-related transcription factor  
MSC, mesenchymal stem cell 
mTOR, mammalian target of rapamycin 
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mTORC1/2, mTOR complex 1 or 2 
MYOCD, myocardin 
NCID, Notch intracellular domain 
NO, nitric oxide (NO) 
OB, osteoblast 
PAH, pulmonary arterial hypertension 
PDGF, platelet-derived growth factor 
PDGFR, platelet-derived growth factor receptor 
PECAM, platelet endothelial cell adhesion molecule 
PI3K, phosphatidylinositol-3-kinase 
PIP3, phosphatidylinositol (3,4,5)-tris-phosphate 
PKC, protein kinase C 
PKG I α, cGMP-dependent protein kinase alpha 
ROCC, receptor operated Ca2+ channels 
S1P, sphingosine 1 phosphate 
SBE, Smad-binding element 
SCAI, suppressor of cancer cell invasion 
SM, smooth muscle 
SMC, Smooth muscle cell 
SRF, serum response factor 
SVD, small vessel disease 
Rho-kinase, Rho-associated kinase 
TAZ, transcriptional coactivator with a PDZ-binding domain 
TCE, TGF-β control elements 
TCF, ternary complex factors  
TCF/LEF, T-cell factor/lymphoid enhancer factor 
TET, Ten-Eleven-Translocation  
TGF-β, transforming growth factor-β 
VSMC, vascular smooth muscle cell 
VEGFR2, vascular endothelial growth factor receptor 2 
YAP, YES associated protein 
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